Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study.

Date publication

février 2022

Journal

Lung cancer (Amsterdam, Netherlands)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline

Tous les auteurs :
Paz-Ares L, Gondos A, Saldana D, Thomas M, Mascaux C, Bubendorf L, Barlesi F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35397297

Résumé

According to 2018 United States and international lung cancer and pathology guidelines, testing of EGFR, ALK, ROS1 and BRAF genes is a minimum requirement to identify targeted therapy options in patients with advanced non-small cell lung cancer (aNSCLC). We describe real-world use and clinical features of next-generation sequencing (NGS) and other non-NGS testing technologies in these patients.

Mots clés

Gene expression profiling, Genetic information databases, Next-generation sequencing, Non-small cell lung cancer, Targeted molecular therapy, Tumor biomarker

Référence

Lung Cancer. 2022 Feb 3;167:41-48